Evidence map›Paper›PMID 25981462›Full record

ReviewArthritis research & therapy2015

Mass cytometry as a platform for the discovery of cellular biomarkers to guide effective rheumatic disease therapy.

Nitya Nair, Henrik E Mei, Shih-Yu Chen, Matthew Hale, Garry P Nolan, Holden T Maecker, Mark Genovese, C Garrison Fathman, Chan C Whiting

Registry-linked trialAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Arthritis research & therapy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03885713 (Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches), which is not on this map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03885713 phase4completednot on this mapstarted 2019, after this paper: background citation

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches

TypeinterventionalSponsorFundación de Investigación Biomédica - Hospital Universitario de La PrincesaRan2019 to 2024Enrolled180ConditionsInflammatory Bowel Diseases, Crohn Disease, Ulcerative ColitisArmsInfliximab or adalimumab or golimumab or vedolizumab or ustekinumab or tofacitinib
3 · Its place in the literature

Who cites it

32 citing papers in PubMed.

  1. Article
  2. Article
  3. Deciphering the aging process through single-cell cytometric technologies.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2024
    Review
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. How Clinical Flow Cytometry Rebooted Sepsis Immunology.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2019
    Review
  17. Optimization of Receptor Occupancy Assays in Mass Cytometry: Standardization Across Channels with QSC Beads.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2019
    Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nitya NairDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, 94305, USA. nnair@aduro.com.
Henrik E MeiInstitute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, 94305, USA. hemei@stanford.edu.
Shih-Yu ChenDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, 94305, USA. siychen@stanford.edu.
Matthew HaleDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, 94305, USA. mhale@stanford.edu.
Garry P NolanDepartment of Microbiology and Immunology, Stanford University, Stanford, CA, 94305, USA. gnolan@stanford.edu.
Holden T MaeckerInstitute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA, 94305, USA. maecker@stanford.edu.
Mark GenoveseDepartment of Medicine, Stanford University, Stanford, CA, 94305, USA. genovese@stanford.edu.
C Garrison FathmanDepartment of Medicine, Stanford University, Stanford, CA, 94305, USA. cfathman@stanford.edu.
Chan C WhitingDivision of Immune Monitoring and Biomarker Development, Aduro BioTech, Inc., Berkeley, CA, 94710, USA. cwhiting@aduro.com.

Funding

Supplement - Inflammatory Triggers in B Cell AutoimmunityU19AI056363 · NIAID · DUKE UNIVERSITY · PI ST. CLAIR, EUGENE WILLIAM · 2003 to 2017
$35.3M
NIAID NIH HHS U19 AI056363NIAID NIH HHS U19 AI056363-08 T11-SU
6 · The paper itself

Abstract

The development of biomarkers for autoimmune diseases has been hampered by a lack of understanding of disease etiopathogenesis and of the mechanisms underlying the induction and maintenance of inflammation, which involves complex activation dynamics of diverse cell types. The heterogeneous nature and suboptimal clinical response to treatment observed in many autoimmune syndromes highlight the need to develop improved strategies to predict patient outcome to therapy and personalize patient care. Mass cytometry, using CyTOF®, is an advanced technology that facilitates multiparametric, phenotypic analysis of immune cells at single-cell resolution. In this review, we outline the capabilities of mass cytometry and illustrate the potential of this technology to enhance the discovery of cellular biomarkers for rheumatoid arthritis, a prototypical autoimmune disease.

Indexed as

Arthritis, RheumatoidBiomarkersFemaleHumansMaleMass SpectrometrySensitivity and SpecificitySeverity of Illness IndexSingle-Cell AnalysisBiomarkers

Identifiers

PMID25981462
PMCPMC4436107

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.